Citigroup’s MoonLake Immunotherapeutics MLTX Stock Holding History

Citigroup’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$255K	Buy	13,691 +12,781	+1,405%	+$212K	﹤0.01%	3888
2025 Q4	$12K	Sell	910 -7,111	-89%	-$83.9K	﹤0.01%	5005
2025 Q3	$57.5K	Buy	8,021 +5,050	+170%	+$263K	﹤0.01%	4447
2025 Q2	$140K	Sell	2,971 -18,257	-86%	-$744K	﹤0.01%	4245
2025 Q1	$829K	Buy	21,228 +20,016	+1,651%	+$862K	﹤0.01%	3377
2024 Q4	$65.6K	Buy	+1,212	New	+$61.9K	﹤0.01%	5003
2024 Q1	–	Sell	-2,297	Closed	-$139K	–	5776
2023 Q4	$139K	Buy	2,297 +2,265	+7,078%	+$117K	﹤0.01%	4078
2023 Q3	$1.82K	Sell	32 -571	-95%	-$31.5K	﹤0.01%	4986
2023 Q2	$30.8K	Sell	603 -76,673	-99%	-$2.06M	﹤0.01%	4848
2023 Q1	$1.65M	Sell	77,276 -89,041	-54%	-$1.5M	﹤0.01%	2150
2022 Q4	$1.75M	Buy	166,317 +7,230	+5%	+$64.3K	﹤0.01%	2144
2022 Q3	$1.27M	Hold	159,087	–	–	﹤0.01%	2526
2022 Q2	$835K	Buy	+159,087	New	+$1,000K	﹤0.01%	2813

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup's MLTX Position: Q1 2026 in Review

Citigroup increased its MoonLake Immunotherapeutics (MLTX) stake by 1,405% in Q1 2026, buying an estimated $212K and bringing the position to 13,691 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #3888.

Citigroup first reported a position in MLTX in Q2 2022 and has held it in 13 quarters since. The position peaked at $1.75M in Q4 2022. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Citigroup held 13,691 shares of MoonLake Immunotherapeutics worth $255K as of Q1 2026.
Citigroup bought 12,781 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $212K.
MoonLake Immunotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3888 holding.
Citigroup first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 13 quarters since.
Citigroup's MoonLake Immunotherapeutics position peaked at $1.75M in Q4 2022.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.